Savolitinib Plus Durvalumab Induces High Response Rates in MET-Driven Papillary Renal CancerMarch 4th 2023
A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.
Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHDFebruary 2nd 2023
First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
Hepatic Arterial Infusion Chemotherapy-Administered FOLFOX Delivers Longer DFS Rates in Hepatocellular CarcinomaJanuary 9th 2023
Adjuvant treatment with hepatic arterial infusion chemotherapy-infused FOLFOX improved disease-free survival rates for patients with hepatocellular carcinoma with microvascular invasion.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPCOctober 29th 2022
A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.